atezolizumab
chromobody
mapatumumab
-lim-
ocrelizumab
immunofluorohistochemistry
antimouse
antiantibody
histocompatibility antigen
myelosclerosis
immunohistochemical
RAT test
immunocompetent
vaxin
cergutuzumab
antiplasma
teclistamab
antihistone
teprotumumab
cytotoxic reaction
polyvalent
specific
affinity
ravulizumab
tislelizumab
pidilizumab
olaratumab
immunocytic
abagovomab
gevokizumab
recognition
immunosynaptic
brolucizumab
tabalumab
iratumumab
autocentromere
histoimmunochemical
idiospecific
immunoreactively
microlymphocytotoxicity
reagin
immunorepressive
ipilimumab
-les-
antigenic
-ab
preimmunoadsorption